| Secretary's Advisory Committee on Infant Mortality |
Committee, Work group, Advisory group, or Task Force |
CDC, HRSA |
NICHD |
The Secretary’s Advisory Committee on Infant Mortality (SACIM) was formed in 1991 to advise the Secretary on Department of Health and Human Services’ programs that are directed at reducing infant mortality and improving the health status of pregnant women and infants. https://www.hrsa.gov/advisory-committees/infant-mortality/index.html |
| Secretary's Tribal Advisory Committee (STAC) |
Committee, Work group, Advisory group, or Task Force |
IOS |
OD/IMOD |
The Secretary’s Tribal Advisory Committee signals a new level of attention to Government-to-Government relationship between HHS and Indian Tribal Governments.The STAC’s primary purpose is to seek consensus, exchange views, share information, provide advice and/or recommendations; or facilitate any other interaction related to intergovernmental responsibilities or administration of HHS programs, including those that arise explicitly or implicitly under statute, regulation or Executive Order. This purpose will be accomplished through forums, meetings and conversations between Federal officials and elected Tribal leaders in their official capacity (or their designated employees or national associations with authority to act on their behalf). |
| Sepsis Interagency Meeting |
Committee, Work group, Advisory group, or Task Force |
AHRQ, BARDA, CDC, CMS |
NHLBI, NIAID, NICHD, NIGMS |
Discuss Sepsis Priority Areas identified in Biomedical Advanced Research and Development (BARDA) market research: Unifying definitions of Sepsis across the patient continuum, Harmonizing Data for Access and Interoperability, Optimizing Health Outcomes and Reducing Economic Burden, Improving Evaluation and Catalyzing Adoption of Critical Technologies. |
| Sequencing for Public Health Emergency Response, Epidemiology and Surveillance |
Other |
CDC |
NIA, NIAID, NLM |
To accelerate the use of near-real-time pathogen genomic data during the SARS-CoV-2 pandemic and future public health events, the CDC established the Sequencing for Public Health Emergency Response, Epidemiology, and Surveillance (SPHERES) consortium. The consortium works to improve communication and knowledge-sharing among U.S. laboratories, develop consensus guidance on data and metadata standards, reduce barriers to bioinformatics analysis and data sharing, and better align sequencing requirements and resource needs with available sources of funding, technology, expertise, and other resources. https://www.cdc.gov/advanced-molecular-detection/php/spheres/ |
| Sequencing Quality Control Phase 2 (SEQC2) |
Resource Development |
FDA, FDA |
CIT, NCI, NHLBI, NIEHS, NLM |
The Sequencing Quality Control (SEQC) consortium is an FDA-led community-wide effort. SEQC Phase 2 (SEQC2) is a project within the consortium. The goals of SEQC2 are to: (1) develop quality metrics for reproducible next-generation sequencing (NGS) results from both whole genome sequencing (WGS) and targeted gene sequencing (TGS); (2) benchmark bioinformatics methods for WGS and TGS towards the development of standard data analysis protocols; and (3) assess the joint effects of key parameters affecting NGS results and interpretation for clinical application. NLM provides a data portal and supports the effort with data analysis. https://www.fda.gov/science-research/bioinformatics-tools/microarrayseq…; https://ftp.ncbi.nlm.nih.gov/ReferenceSamples/seqc/Somatic_Mutation_WG/ |
| Serum concentrations of per- and polyfluoroalkyl substances and breast cancer risk among postmenopausal women: A nested case-control study in the Women’s Health Initiative (WHI) |
Research Initiative |
CDC |
NCI |
To clarify the potential role of PFAS in the development of breast cancer overall and for specific hormone receptor subtypes, the National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating on measurements of serum concentrations of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of breast cancer among postmenopausal women in the Women’s Health Initiative (WHI) Observational Study. |
| Serum organochlorine/PCB concentrations and risk of prostate cancer in men from Ghana |
Research Initiative |
CDC |
NCI |
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of persistent organic pollutants for a case-control study of prostate cancer in the Ghana Prostate Study. |
| Serum PFAS concentrations and risk of renal cell carcinoma in the Multiethnic Cohort |
Research Initiative |
CDC |
NCI |
National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) are collaborating to measure serum levels of per- and polyfluoroalkyl substances (PFAS) for a nested case-control study of renal cell carcinoma (RCC) in the Multiethnic Cohort. |
| SHIELD: Standardization of Lab Data to Enhance Outcomes Research and Value Based Care |
Committee, Work group, Advisory group, or Task Force |
FDA, CDC, FDA |
NLM |
This project will expand the collaborative efforts of the FDA and other stakeholders involved in the SHIELD (Systemic Harmonization and Interoperability Enhancement for Laboratory Data) initiative to ensure laboratory information interoperability, such that the same type of device is described the same way across electronic health records systems. To achieve this, the project will develop code mapping manuals to consistently map the same LOINC (Logical Observations Identifiers Names and Codes) to the same type of in vitro diagnostic (IVD) devices. This is important because, without specific guidance, manufacturers of IVD devices and laboratories often assign different (and frequently incorrect) LOINC codes for the same type of device. Additionally, the project will pilot the implementation of SHIELD standard digital formats to update infrastructure in active healthcare provider laboratories. This will facilitate the seamless distribution of LOINC and SNOMED-CT (Systematized Nomenclature of Medicine—Clinical Terms) coding to those provider institutions and registries. https://aspe.hhs.gov/shield-standardization-lab-data-enhance-patient-ce… |
| Sickle Cell Disease Federal Interagency Work Group (SCD FIWG) |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA, HRSA, OASH |
NHGRI, NHLBI |
The Sickle Cell Disease Federal Interagency Work Group (FIWG) fosters a community of partners engaged in achieving the vision of long, healthy, productive lives for those living with Sickle Cell Disease (SCD) and those with Sickle Cell Trait (SCT)." This involves building the capacity to address the recommendations shared in the NASEM Sickle Cell Disease Strategic Plan and Blueprint for action. |